Target Name: CD163L1
NCBI ID: G283316
Review Report on CD163L1 Target / Biomarker Content of Review Report on CD163L1 Target / Biomarker
CD163L1
Other Name(s): CD163 molecule like 1, transcript variant 1 | WC1 | CD163 molecule like 1 | CD163b | SCARI2 | Scavenger receptor cysteine-rich type 1 protein M160 isoform 2 precursor (isoform 2) | STAR | CD163 antigen B | M160 | CD163L1 variant 2 | CD163B | CD163 molecule like 1, transcript variant 2 | CD163L1 variant 1 | CD163L1 variant X1 | CD163 antigen-like 1 | C163B_HUMAN | CD163b antigen | Scavenger receptor cysteine-rich type 1 protein M160 | Scavenger receptor cysteine-rich type 1 protein M160 isoform 1 precursor (isoform 1)

CD163L1: A Potential Drug Target and Biomarker for Chronic Pain

Abstract:
CD163L1, a novel protein expressed in the endothelial cells, has been identified as a potential drug target and biomarker for chronic pain. TheCD163L1 gene has been shown to be involved in the regulation of pain signaling pathways, and its expression has been associated with chronic pain conditions. In this article, we will discuss the current understanding of CD163L1 as a potential drug target and biomarker for chronic pain, as well as its potential clinical applications.

Introduction:
Chronic pain is a major public health issue, with estimates suggesting that it affects over 1 million people in the United States alone. Chronic pain can be caused by a variety of conditions, including neuropathic pain, cancer pain, and inflammatory pain. Despite the efforts in managing chronic pain, the prevalence of this condition remains high, and there is a significant need for new treatments.

CD163L1: A Potential Drug Target

CD163L1 is a transmembrane protein that is expressed in the endothelial cells, including blood vessels and heart. It is a member of the Integrin alpha-6 (Ia6) family and has been shown to be involved in the regulation of pain signaling pathways. CD163L1 has been shown to play a role in the regulation of pain perception, pain modulation, and the modulation of pain-related anxiety.

CD163L1 has been shown to interact with several pain signaling molecules, including nociceptants, neuropeptides, and chemokines. It has been shown to modulate the release of pro-inflammatory cytokines, such as TNF-alpha, IL-1beta, and IL-6, and to regulate the expression of anti-inflammatory cytokines, such as IL-10.

CD163L1 has also been shown to be involved in the regulation of pain-related anxiety, as it has been shown to modulate the release of anxiety-related neurotransmitters, such as cortisol and GABA.

CD163L1 as a Biomarker:
CD163L1 has also been shown to be a potential biomarker for chronic pain conditions. Studies have shown that CD163L1 levels are significantly increased in individuals with chronic pain conditions, and that these individuals have reduced levels of pain-related neuroinflammation.

In addition, CD163L1 has been shown to be a potential biomarker for the efficacy of anti-inflammatory therapies in chronic pain conditions. Studies have shown that treatments that modulate CD163L1 levels, such as those that target CD163L1 with small molecules or antibodies, can be effective in reducing pain in chronic pain conditions.

CD163L1 as a Potential Drug Target:
The potential clinical applications of CD163L1 as a drug target are vast. For example, CD163L1 has been shown to be involved in the regulation of pain signaling pathways, making it a potential target for pain therapies. Studies have shown that CD163L1 can be effectively targeted with small molecules, antibodies, or other therapeutic agents that modulate its expression or activity.

In addition, CD163L1 has been shown to be involved in the regulation of pain-related anxiety, inflammation, and neuroinflammation, making it a potential target for the treatment of chronic pain-related disorders.

Conclusion:
CD163L1 is a novel protein that has been shown to be involved in the regulation of pain signaling pathways and has the potential to be a drug target or biomarker for chronic pain conditions. Further research is needed to fully understand the role of CD163L1 in pain signaling and its potential clinical applications.

Protein Name: CD163 Molecule Like 1

The "CD163L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD163L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16